A phase 2 study of the combination of PLK1 inhibitor, onvansertib, with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer
Year: 2019
Type: conference-abstract
Source: European Urology Supplements
Authors: D.J. Einstein, A. Choudhury, P. Saylor, L. Werner, M. Erlander, G. Bubley
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2985416373